Options
BMI-1調控非小細胞肺癌之Pemetrexed抗藥性機轉的研究
Date Issued
2021
Author(s)
沈煥庭
Huan-Ting Shen
Advisor
Abstract
肺癌是世界上癌症相關死因中的首位。其治療策略包含手術、化學治療和放射線治療。肺癌當中約85%是非小細胞肺癌。Pemtrexed這種抗葉酸藥物是目前治療第三、四期非小細胞肺癌的第二線化療藥物,其治療反應率為20-40%。尋找合併治療以提高pemetrexed的治療效果是臨床上所需要的。而為了延長pemetrexed的有效療程,辨識及克服產生出抗藥性的癌細胞也是重要的工作。癌症幹細胞的存在被認為是癌症產生化療藥物抗藥性的主要原因之一。在本實驗裡,我們使用具有pemetrexed抗藥性的非小細胞肺癌細胞名為A400細胞,其來自中山醫學大學醫學研究所許國堂教授實驗室,是從A549非小細胞肺癌細胞建立而來且擁有pemetrexed抗藥性的細胞。我們首先發現A400細胞比A549細胞表現出較高的癌症幹細胞活性。在A400細胞中,和癌症幹細胞表現有關的蛋白像是BMI1或CD44,以及上皮間質轉化(epithelial-mesenchymal transition, EMT)路徑表現皆是增加的。我們接著發現A400細胞中BMI1的過度表現導致pemetrexed抗藥性;而使用PTC-209的小分子抑制劑或是導入BMI1特異性的shRNAs來抑制BMI1的表現後,可見到A400細胞生長及其胸苷酸合成酶(thymidylate synthase, TS, gene name : TYMS)活性也被抑制。我們更進一步確認BMI1正向調控SP1的表現,而使用SP1抑制劑,mithramycin A,則能抑制A400細胞增生和其TS的表現。再者,A400細胞中BMI1的過度表現使得EMT路徑活化及癌症幹細胞活性增強。最後,我們證明帶有pemetrexed抗藥性腫瘤的小鼠,在預先接受過PTC-209處理後,其身上的腫瘤能對pemetrexed治療產生反應,而腫瘤的Ki-67、BMI1、SP1表現也被觀察到是減少的。綜合以上結果,BMI1的表現影響了非小細胞肺癌對pemetrexed治療的敏感性。當非小細胞肺癌病人對pemetrexed抗產生藥性的時候,使用抑制BMI1的小分子藥物將會是有效的治療策略。
Lung cancer is the leading cause of cancer death worldwide and the therapeutic strategies include surgery, chemotherapy and radiation therapy. The non-small cell lung cancers (NSCLCs) account for around 85% cases of lung cancers. Pemetrexed is an antifolate agent that currently used as the second line chemotherapy drug in the treatment of advanced NSCLC patients with a response rate of 20-40%. To search for any combination therapy to improve the efficacy of pemetrexed is required. The existence of cancer stem cells (CSCs) is considered as one of the main reasons for the drug resistance of cancers. In this study, we used pemetrexed resistant NSCLC cells named A400 cells, which were derived from A549 cells and developed in Prof. Gwo-Tarng Sheu’s lab in Institute of Medicine, Chung Shan Medical University. We first found that these A400 cells displayed higher CSC activity in comparison to the parental cells. The expression of CSC related proteins, such as BMI1 or CD44, and the epithelial-mesenchymal transition (EMT) signature was elevated in pemetrexed resistant NSCLC cells. We next discovered that the overexpression of BMI1 in A400 cells caused the pemetrexed resistance and inhibition of BMI1 by a small molecule inhibitor, PTC-209, or transducing of BMI1-specific shRNAs suppressed cell growth and the expression of thymidylate synthase (TS) in A400 cells. We further identified that BMI1 positively regulated SP1 expression and treatment of mithramycin A, a SP1 inhibitor, inhibited cell proliferation, as well as TS expression, of A400 cells. Furthermore, overexpression of BMI1 in A400 cells also caused the activation of EMT in and the enhancement of CSC activity. Finally, we demonstrated that pretreatment of PTC-209 in mice bearing A400 tumors sensitized them to pemetrexed treatment and the expression of Ki-67, BMI1, and SP1 expression in tumor tissues was observed to reduced. In conclusion, BMI1 expression level mediates pemetrexed sensitivity of NSCLC cells and the EMT/CSC characteristics of pemetrexed resistant NSCLC cells. The inhibition of BMI1 will be an effective strategy in NSCLC patients when developed pemetrexed resistance.
Subjects
BMI1
SP1
Pemetrexed抗藥性
非小細胞肺癌
癌症幹細胞
上皮間質轉化
pemetrexed resistance
non-small cell lung cancer
cancer stem cells
epithelial-mesenchymal transition
Type
thesis
File(s)
No Thumbnail Available
Name
109CSMU5534025-001.zip
Size
2.71 MB
Format
Unknown
Checksum
(MD5):f7d9b45689dff814ec124486a9d5e21c